Human medicines European public assessment report (EPAR): Zepatier, elbasvir,grazoprevir, Date of authorisation: 22/07/2016, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Yesintek, ustekinumab, Date of authorisation: 14/02/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Date of authorisation: 23/08/2012, Revision: 17, Status: Authorised

HMA/EMA multi-stakeholder workshop on artificial intelligence, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 November 2025, 13:30 (CET) to 21 November 2025, 12:45 (CET)

Human medicines European public assessment report (EPAR): Bridion, sugammadex, Date of authorisation: 25/07/2008, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Temodal, temozolomide, Date of authorisation: 26/01/1999, Revision: 40, Status: Authorised

Referral: Veterinary medicinal products containing amoxicillin, amoxicillin Article 141(1)(i) procedures Procedure started

Human medicines European public assessment report (EPAR): Quadramet, samarium [153Sm] lexidronam pentasodium, Date of authorisation: 04/02/1998, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Entecavir Viatris (previously Entecavir Mylan), entecavir, Date of authorisation: 18/09/2017, Revision: 10, Status: Authorised